This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sindermann, J. R. Articles by March, K. L. Search for Related Content PubMed PubMed Citation Articles by Sindermann, J. R. Articles by March, K. L.

(Circulation. 1998;97:2486-2490.)
© 1998 American Heart Association, Inc.

Editorials

Heparin Responsiveness In Vitro as a Prognostic Tool for Vascular Graft Stenosis

A Tale of Two Cell Types?

Jürgen R. Sindermann, MD; ; Keith L. March, MD, PhD

From the Krannert Institute of Cardiology, R.L. Roudebush VA Medical Center, and Indiana University Medical Center, Indianapolis, Ind.

Correspondence to Keith L. March, MD, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, 1111 W 10th St, Indianapolis, IN 46254. E-mail march@kimail.dmed.iupui.edu

Key Words: Editorials • heparin • stenosis • muscle, smooth

Vascular graft stenosis after infrainguinal vein grafting or coronary artery bypass graft surgery is a significant cause of morbidity and suboptimal long-term clinical outcome of patients with vascular disease. Numerous animal and clinical studies have been undertaken to reveal the pathophysiological mechanisms accounting for this detrimental process. Stenotic lesions are dominated by neointima formation with migration and proliferation of SMCs and deposition of extracellular matrix. This appears to be a conserved response in the vasculature not only after vein grafting but also after various injurious stimuli such as angioplasty, endarterectomy, embolectomy, and arterial catheterization. However, the mechanisms of the process of stenosis are still not fully understood, and there is neither an effective treatment for prevention nor a diagnostic test for reliable prediction of patients at risk for developing graft stenosis. Most clinical and experimental studies have focused on the control of SMC proliferation with the intention of developing strategies for the prophylaxis of restenosis, whereas relatively little has been achieved in the area of early tests to define the prognosis and need for clinical monitoring of particular patients.

The anticoagulant heparin has been used for many years in the therapy and prophylaxis of thrombotic conditions. It is also known for its antiproliferative effects on SMCs when applied in higher doses and has been studied extensively in animal models and clinical studies for the inhibition of neointima formation after vascular injury. As for many other compounds, encouraging results obtained in animal models have not been matched by successful clinical studies, . . . [Full Text of this Article]